Tuesday, August 12, 2025

Polaris of Enlightenment

Concern in the vaccine industry after Kennedy’s nomination

Published 16 November 2024
– By Editorial Staff
RFK and Donald Trump during a campaign rally in Arizona.
2 minute read

Share prices for a range of vaccine manufacturers and pharmaceutical companies around the world fell sharply on Friday.

The reason is widespread concern about what Trump’s nomination of vaccine critic Robert F. Kennedy Jr. as secretary of health could mean for the historically lucrative sector.

Kennedy has vowed to crack down on Big Pharma and wants vaccines to be voluntary, safe and properly tested – and to fight corruption and powerful special interests in US public health.

Today, he says, no one knows exactly how dangerous vaccines are or whether they even prevent more problems than they cause. Kennedy also believes that not a single vaccine in the US vaccine program has been tested thoroughly enough to safely assess its risks and benefits.

The news that Trump has nominated RFK as the new Secretary of Health and Human Services was thus not received positively by industry players and in the US, shares in Pfizer fell by more than 4%, Moderna by about 7% and Astra Zeneca and GSK by more than 3% on Friday.

 

According to Russ Mould, director at investment platform AJ Bell, the election has “spooked” many of the pharmaceutical companies’ shareholders and led to concerns about the future of the companies if Kennedy’s nomination goes through.

– The impact on the sector is hard to judge fully at this stage but, at the very least, it will cause a good deal of uncertainty, he says.

Wants to see a number of changes

If Kennedy becomes the new health secretary, he would head a large and well-resourced agency that oversees everything from food safety to medical research and national health programs including mass vaccination programs.

Kennedy has also called for more restrictions and bans on chemicals and dyes in food, the removal of ultra-processed foods from school lunches, and for pharmaceutical companies to be forced to be more transparent and share more information about their products than they do today.

The pharmaceutical industry is also concerned that with Trump as president, there will be less money to be made in the US market as the president-elect wants to make it easier to import medicines from Canada.

“Have to wait and see”

Danish vaccine maker Bavarian Nordic’s shares fell more than 15% on Friday but its CEO Paul Chaplin is urging shareholders to wait and see what changes Trump’s presidency will bring to the industry.

He points out that during Donald Trump’s first term, the company’s smallpox and monkeypox vaccine business actually benefited and that it’s hard to say what will happen this time.

– It is too early to say and we have to wait and see how things develop.

Danish Novo Nordisk and French Sanofi also fell sharply on Friday, with their shares dropping by just over five percent and just over three percent respectively.

TNT is truly independent!

We don’t have a billionaire owner, and our unique reader-funded model keeps us free from political or corporate influence. This means we can fearlessly report the facts and shine a light on the misdeeds of those in power.

Consider a donation to keep our independent journalism running…

Swedish banks urged to take responsibility for failing cash system

The war on cash

Published today 13:53
– By Editorial Staff
Every fourth ATM has been closed in recent months, leading to demands that banks take responsibility for cash handling.
2 minute read

About one in four ATMs from Bankomat has been closed during recent months. Now the Cash Revolt movement (Kontantupproret) is demanding that Swedish banks take responsibility.

Bankomat AB is owned by Sweden’s major banks: Swedbank, Handelsbanken, Nordea, Danske Bank, and SEB. For several months, the company has experienced major problems with its ATMs, with approximately 25-30 percent of all machines in the country being shut down. In some smaller towns, such as Söderhamn in central Sweden, all ATMs in the entire municipality were closed.

We can do nothing but apologize. This is completely unacceptable, said Jenny Danielsson, press officer at Bankomat, to Söderhamns-kuriren.

The cause stems from the company taking over cash transport to and from the machines themselves at the beginning of the year, a service they had previously outsourced. However, this proved to be a more “complex task” than initially expected, with the main problem being that the system used for counting money is not functioning properly, as the company has explained on its website.

Now the Cash Revolt movement (Kontantupproret) is demanding that the bank owners take responsibility for cash handling and open their bank branches when ATMs are not functioning.

Nordea, Swedbank, SEB, Handelsbanken and Danske Bank together have a large network of offices across the country. They should agree to keep at least one of their offices open in locations where there are problems. In the past, all bank branches handled cash, so it’s not particularly difficult for them. It’s about time they started taking their social responsibility and helped people access cash, says Björn Eriksson, chairman of the Cash Revolt movement, in a press release.

Government must act

Behind the organization, which describes itself as the voice of cash in society, are groups including the youth organization Förbundet Vi Unga, rural advocacy group Hela Sverige ska leva, Sveriges Konsumenter, and the Federation of Swedish Small Businesses. The Cash Revolt movement believes that cash supply issues should be handled through democratic processes rather than left to the private banking system to decide.

If banks don’t take action and open their offices, the Swedish government should intervene, the organization argues.

It’s strange that banks don’t act voluntarily. The problems with Bankomat have been ongoing for a long time and also show how vulnerable our cash system is today. It’s as if bank management has become too comfortable in their offices and doesn’t care how ordinary people are affected. The government must start pointing the finger, says Eriksson.

EU and US reach agreement on tariffs and energy cooperation

Published 28 July 2025
– By Editorial Staff
Ursula von der Leyen and Donald Trump in connection with yesterday's press conference.
3 minute read

The EU and US have reached agreement on a comprehensive trade deal that involves 15 percent American import tariffs on the majority of EU goods. The agreement marks an important step toward stability and predictability in transatlantic trade.

After months of tense negotiations, a new trade agreement between the EU and US was announced yesterday.

The agreement means that the US will impose a general tariff rate of 15 percent on the majority of EU exports to the US, including products from the automotive industry. Exceptions are made for steel and aluminum, which continue to be regulated under separate quota systems.

European Commission President Ursula von der Leyen and US President Donald Trump presented the agreement after meetings in Scotland, where they described it as “all inclusive” and a breakthrough that creates stability in an uncertain global economic situation.

I think this is the biggest deal ever made, Trump said during a press conference celebrating the agreement.

The agreement also includes significant energy cooperation where the EU commits to investing in and purchasing American energy worth $750 billion.

European Commission President Ursula von der Leyen commented on the agreement in positive terms: – We have a trade deal between the two largest economies in the world, and it’s a big deal. It’s a huge deal. It will bring stability. It will bring predictability.

Agreement faces criticism: “Unbalanced”

Additionally, the EU plans to make investments of $600 billion in the US over a longer period. This includes liquefied natural gas (LNG), oil and nuclear fuel, which is seen as part of the EU’s ambition to reduce dependence on Russian energy.

The trade agreement further includes tariff-free trade on selected strategic products such as aircraft, aircraft parts, semiconductors and certain chemicals, which is expected to benefit both parties’ industrial sectors. However, some uncertainty remains regarding tariff rates on certain agricultural products and beverages.

The agreement averts a looming tariff conflict where the US had previously threatened up to 50 percent import tariffs on European goods, a level that was later reduced to 30 percent before the final agreement was reached.

Many in Europe still consider the baseline level of 15 percent too high, particularly in light of original hopes for a zero-to-zero agreement.

Criticism also comes against what many consider a worse deal for EU member states compared to the agreement concluded between the US and the UK – a UK that moreover stands outside the EU.

Bernd Lange, a German Social Democrat and chair of the European Parliament’s trade committee, sees the tariffs as “unbalanced”. He warns that the extensive EU investments now directed toward the US will likely come at the expense of the EU itself.

European companies largely welcome the agreement, which is expected to contribute to increased trade and investment across the Atlantic, while the agreement signals new opportunities for cooperation in energy and technology.

Fact box: WTO, tariffs and trade conflicts

  • WTO's role: The World Trade Organization (WTO) regulates international trade and aims to minimize tariffs and other trade barriers between member countries.
  • Tariffs: Taxes on imported goods that affect prices and competitiveness. High tariffs can reduce trade and lead to negative economic effects globally.
  • Trade wars: Escalated tariff increases between countries, which the US and EU came close to initiating, can damage exports and imports, worsen relations and create market uncertainty.
  • Economic effects: Stability and low tariffs promote investment and growth. The agreement between the EU and US is expected to reduce the risk of trade tensions and enable long-term planning for companies on both sides.
  • Energy and geopolitics: The energy component of the agreement is linked to Europe's energy transition and its ambition to reduce dependence on Russian gas and oil through American energy sources.

AstraZeneca invests billions in the US

Published 23 July 2025
– By Editorial Staff
1 minute read

AstraZeneca plans to invest $50 billion in the USA. The investment comes in the wake of Donald Trump’s threats of import tariffs, and includes a new pharmaceutical factory in Virginia.

The Swedish-British pharmaceutical company announced on Monday that the plan is to reach an annual revenue of $80 billion by 2030, where half of the revenue should come from the USA. To achieve this, the company will invest $50 billion, on American soil, announced CEO Pascal Soriot during a visit to Washington, writes Reuters.

The investment includes a new pharmaceutical factory in the state of Virginia, which will also become AstraZeneca’s largest single manufacturing investment ever. Furthermore, it also includes expansions in Maryland, Texas and Massachusetts.

Threat of import tariffs

The investment in the country is the latest in a series of similar measures from other pharmaceutical companies after President Donald Trump threatened import tariffs and expressed demands for increased domestic production. Trump has repeatedly threatened tariffs on the pharmaceutical sector, but signaled earlier this month that companies would have one to 18 months to “get their act together” before any fees take effect.

Among others, pharmaceutical company Johnson & Johnson, which operates in over 150 countries, also plans to invest $55 billion in the country over the next four years. The Swiss company Roche also plans to invest $50 billion in the USA.

Already last year, the USA accounted for more than 40 percent of AstraZeneca’s revenue. In total, the company currently has 19 facilities and offices in the USA with over 18,000 employees.

Our independent journalism needs your support!
We appreciate all of your donations to keep us alive and running.

Our independent journalism needs your support!
Consider a donation.

You can donate any amount of your choosing, one-time payment or even monthly.
We appreciate all of your donations to keep us alive and running.

Dont miss another article!

Sign up for our newsletter today!

Take part of uncensored news – free from industry interests and political correctness from the Polaris of Enlightenment – every week.